Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial

AIMS/INTRODUCTION: Recent clinical trials on sodium–glucose cotransporter 2 inhibitors showed improved outcomes in patients with type 2 diabetes at a high risk of cardiovascular events. However, the underlying effects on endothelial function remain unclear. MATERIALS AND METHODS: The effect of empag...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Shimabukuro, Michio, Machii, Noritaka, Teragawa, Hiroki, Okada, Yosuke, Shima, Kosuke R., Takamura, Toshinari, Taguchi, Isao, Hisauchi, Itaru, Toyoda, Shigeru, Matsuzawa, Yasushi, Tomiyama, Hirofumi, Yamaoka‐Tojo, Minako, Ueda, Shinichiro, Higashi, Yukihito, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610132/
https://www.ncbi.nlm.nih.gov/pubmed/32537887
http://dx.doi.org/10.1111/jdi.13289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610132/
https://www.ncbi.nlm.nih.gov/pubmed/32537887
http://dx.doi.org/10.1111/jdi.13289

Ejemplares similares